{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bendamustine&page=2", "query": { "intervention": "bendamustine", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bendamustine&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-03T17:26:07.409Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01088048", "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Indolent Non-Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Chlorambucil", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2010-03-25", "completion_date": "2015-04-28", "has_results": true, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-09-03T17:26:07.409Z", "location_count": 11, "location_summary": "Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088048" }, { "nct_id": "NCT00856830", "title": "Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Extensive Stage Lung Cancer", "Chemonaive" ], "interventions": [ { "name": "Novel Drug Combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 30, "start_date": "2009-04", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-07-17", "last_synced_at": "2026-09-03T17:26:07.409Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Marietta, Georgia", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00856830" }, { "nct_id": "NCT04892277", "title": "CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Small Lymphocytic Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2022-10-03", "completion_date": "2040-03-27", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-09-03T17:26:07.409Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04892277" }, { "nct_id": "NCT04217317", "title": "CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed T-Cell Lymphoma", "Refractory T-Cell Lymphoma", "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "CPI 613", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-09-16", "completion_date": "2024-07-11", "has_results": true, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-09-03T17:26:07.409Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04217317" }, { "nct_id": "NCT02972840", "title": "A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Mantle Cell" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 635, "start_date": "2017-04-05", "completion_date": "2027-02-15", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-03T17:26:07.409Z", "location_count": 32, "location_summary": "Tucson, Arizona • Downey, California • Santa Monica, California + 27 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Downey", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02972840" }, { "nct_id": "NCT01831505", "title": "Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Presage Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2012-11", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2017-02-27", "last_synced_at": "2026-09-03T17:26:07.409Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01831505" }, { "nct_id": "NCT01049945", "title": "Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma" ], "interventions": [ { "name": "bendamustine hydrochloride", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2010-02", "completion_date": "2015-09-16", "has_results": true, "last_update_posted_date": "2020-02-11", "last_synced_at": "2026-09-03T17:26:07.409Z", "location_count": 5, "location_summary": "Duarte, California • Jacksonville, Florida • Chicago, Illinois + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01049945" }, { "nct_id": "NCT01458366", "title": "Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "CT Scan", "type": "PROCEDURE" }, { "name": "PET Scan", "type": "PROCEDURE" }, { "name": "Stem Cell Transplant (STC)", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "GENETIC" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2011-11-09", "completion_date": "2020-07-23", "has_results": true, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-09-03T17:26:07.409Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01458366" }, { "nct_id": "NCT00984542", "title": "Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bendamustine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2009-09", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2014-03-12", "last_synced_at": "2026-09-03T17:26:07.409Z", "location_count": 6, "location_summary": "Elizabethtown, Kentucky • Germantown, Tennessee • Jackson, Tennessee + 2 more", "locations": [ { "city": "Elizabethtown", "state": "Kentucky" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "Jackson", "state": "Tennessee" }, { "city": "Knoxville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00984542" }, { "nct_id": "NCT03406156", "title": "A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 120, "start_date": "2018-08-10", "completion_date": "2023-07-12", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-09-03T17:26:07.409Z", "location_count": 15, "location_summary": "Tempe, Arizona • Denver, Colorado • Kansas City, Missouri + 12 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03406156" } ] }